As President Trump moves from campaigning to governing, he has reframed several themes. Embedded in his first address to Congress, an illustration of the need for regulatory reform was aimed squarely at the FDA. While we agree that achieving faster medical progress is the goal, and that the FDA must keep pace with 21st century science, we can’t get there by ignoring the facts on the ground. The FDA is the most responsive -- that is, speediest -- drug and device regulating agency in the world, all the while assuring the highest of safety standards. FDA’s excellence in delivering on its mission is not the problem, bandwidth is; the agency must have more robust funding support if it is to do more of what it already does very well indeed. In addition, in order for the FDA to receive and review more -- and more innovative -- applications, both public and private research discovery entities, in both the public and private sector, must be adequately funded and policies enacted that incentivize them to succeed, and to do so more quickly. There will be more to say on this topic in the months ahead, and more advocacy to do! Meanwhile, as the President’s campaign pledge to renew our nation’s infrastructure has come back into focus, it’s important that all of us who are committed to making this a healthier nation urge the Administration and the Congress to include renewal of our public health infrastructure in long overdue make-overs.